Inhaled therapies, azithromycin and Mycobacterium abscessus in cystic fibrosis patients

被引：35

作者：

Catherinot, Emilie ^{[1
,2
,3
,4
]}

Roux, Anne-Laure ^{[1
,2
,3
]}

Vibet, Marie-Anne ^{[5
,6
]}

Bellis, Gil ^{[7
]}

Lemonnier, Lydie ^{[8
]}

Le Roux, Evelyne ^{[8
]}

Bernede-Bauduin, Claire ^{[5
,6
]}

Le Bourgeois, Muriel ^{[9
]}

Herrmann, Jean-Louis ^{[1
,2
,3
]}

Guillemot, Didier ^{[5
,6
,10
]}

Gaillard, Jean-Louis ^{[1
,2
,3
]}

机构：

[1] Hop Raymond Poincare, Microbiol Lab, Paris, France

[2] Hop Ambroise Pare, AP HP, F-92104 Boulogne, France

[3] Univ Versailles St Quentin En Yvelines, EA3647, Guyancourt, France

[4] Hop Foch, Serv Pneumol, Suresnes, France

[5] INSERM, U657, Paris, France

[6] Inst Pasteur, PhEMI, Paris, France

[7] Inst Natl Etud Demog, F-75675 Paris, France

[8] Assoc Vaincre Mucoviscidose, Paris, France

[9] Hop Necker Enfants Malad, AP HP, Serv Pneumol Pediat, Paris, France

[10] Hop Raymond Poincare, AP HP, Serv Med Aigue, Garches, France

来源：

EUROPEAN RESPIRATORY JOURNAL | 2013年 / 41卷 / 05期

关键词：

Macrolides; Mycobacterium bolletii; Mycobacterium massiliense; nontuberculous mycobacteria lung disease; risk factor; NONTUBERCULOUS MYCOBACTERIA; STENOTROPHOMONAS-MALTOPHILIA; INFECTION; ACIDIFICATION; CHILDREN; MACROPHAGES; PREVALENCE; MACROLIDES; PNEUMONIA; DIAGNOSIS;

D O I：

10.1183/09031936.00065612

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Cystic fibrosis (CF) patients are at particularly high risk of developing lung disease caused by Mycobacterium abscessus complex (MABSC). Over the last 10 years, changes in CF treatment, with increasing use of inhaled therapies and low-dose azithromycin, have been accompanied by an increase in the prevalence of MABSC infections in CF patients. There is therefore some concern about the role of new CF treatments in the emergence of MABSC infections. We addressed this issue by means of a case control study including 30 MABSC-positive cases and 60 nontuberculous mycobacteria-negative CF controls matched for age, sex and centre. We also compared practices at the CF centres with the highest prevalence of MABSC with those at the other centres. No positive association was found between MABSC lung disease and the use of inhaled therapies or low-dose azithromycin in the 4 years preceding MABSC isolation. These treatments were not significantly more frequently used at the CF centres with the highest MABSC prevalence rates. In conclusion, there is no evidence for a link between M. abscessus complex lung disease and inhaled therapies or low-dose azithromycin in patients with CF.

引用

页码：1101 / 1106

页数：6

共 37 条

[1] Assessment of Clarithromycin Susceptibility in Strains Belonging to the Mycobacterium abscessus Group by erm(41) and rrl Sequencing [J].